MCAM and myeloid sarcoma: Importantly, treatment with the anti-CD146 functional antibody AA98 ameliorates neuroinflammation but appears to not disturb the host’s protective immune response.18,20 Given the similarities in the pathophysiological features and BBB dysfunction in CM and MS, we sought to determine whether targeting CD146 alleviated neuroinflammation and BBB damage and improved survival in mice with late-stage eCM.